Our technology
Our proprietary CodeEvolver® technology platform has the power to transform the performance of an enzyme, tailoring it for a specific application and process. Using powerful machine learning tools and sophisticated molecular, cellular, and bioanalytical workflows, we design and screen semi-rational libraries of thousands of variants in high throughput every 2-4 weeks on each project, sequencing every variant and correlating its sequence with its performance in a highly application-relevant screen.
Content-rich libraries screened under real-world conditions yield dense datasets, and multiple parameters can be optimized in parallel. The resulting evolved variants often have a combination of enhanced properties, such as increased activity, specificity, stability under desired conditions, or improved expression in the expression host. These enhanced properties provide differentiated technical performance in the target application and ROI in commercial deployment.
Our application
We apply the CodeEvolver® technology platform to engineer enzymes for a wide variety of applications, developing differentiated products in a diverse array of market.
GI-stable oral biologics as potential PKU treatment
Treatment options for PKU are very limited. We engineered CDX-6114 to be an orally administered, GI-stable therapeutic enzyme that can potentially remove phenylalanine from the body before it reaches toxic levels. The program was licensed to Nestle Health Science and is currently in clinical trials.
GI-stable oral biologics as potential PKU treatment
Treatment options for PKU are very limited. We engineered CDX-6114 to be an orally administered, GI-stable therapeutic enzyme that can potentially remove phenylalanine from the body before it reaches toxic levels. The program was licensed to Nestle Health Science and is currently in clinical trials.
Enhancing efficacy for Fabry Disease gene therapies
Fabry patients are in need of long-term efficacious treatments. In collaboration with Takeda our unique protein variant, CDX-6311, which was engineered for stability, activity, and reduced immunogenicity has shown promising results in pre-clinical studies when used as transgene for gene therapy.
Enhancing efficacy for Fabry Disease gene therapies
Fabry patients are in need of long-term efficacious treatments. In collaboration with Takeda our unique protein variant, CDX-6311, which was engineered for stability, activity, and reduced immunogenicity has shown promising results in pre-clinical studies when used as transgene for gene therapy.
Life Sciences
Enabling novel Fully Enzymatic Synthesis™ through enzyme evolution
Chemical synthesis of oligonucleotides is challenged by length and purity limits. Codexis and Molecular Assemblies partnered to evolve a novel terminal deoxynucleotidyl transferase (TdT) enzyme to achieve high nucleotide incorporation rates, a key technology milestone for platform viability.
Enabling novel Fully Enzymatic Synthesis™ through enzyme evolution
Chemical synthesis of oligonucleotides is challenged by length and purity limits. Codexis and Molecular Assemblies partnered to evolve a novel terminal deoxynucleotidyl transferase (TdT) enzyme to achieve high nucleotide incorporation rates, a key technology milestone for platform viability.
Evolving a more powerful enzyme for mRNA synthesis
mRNA-based therapies require the efficient manufacture and capping of synthetic mRNA. We developed Codex® HiCap RNA Polymerase to increase the yield of fully capped mRNA, while also reducing the amount of immunogenic double-stranded RNA byproduct generated.
Evolving a more powerful enzyme for mRNA synthesis
mRNA-based therapies require the efficient manufacture and capping of synthetic mRNA. We developed Codex® HiCap RNA Polymerase to increase the yield of fully capped mRNA, while also reducing the amount of immunogenic double-stranded RNA byproduct generated.
Pharmaceutical Manufacturing
Doubling productivity in the manufacture of APIs for Merck
Improving API manufacturing processes is a challenge for pharmaceutical companies. Merck was faced with the prospect of building a second factory to meet the demand for its blockbuster drug Januvia®. A novel biocatalyst was developed to enable a significantly more efficient process, negating the need for a new facility.
Doubling productivity in the manufacture of APIs for Merck
Improving API manufacturing processes is a challenge for pharmaceutical companies. Merck was faced with the prospect of building a second factory to meet the demand for its blockbuster drug Januvia®. A novel biocatalyst was developed to enable a significantly more efficient process, negating the need for a new facility.
Rapid scaling supports Pfizer in delivering a key treatment for COVID-19
As the world faced the worst pandemic in living memory, global pharmaceutical companies strove to rapidly discover and scale drug candidates which could address COVID-19. Codexis was able to support Pfizer in the synthesis of a critical intermediate for their COVID-antiviral, with a multi-ton production of enzyme to support tens of millions of treatments within a year from first clinical supply.
Rapid scaling supports Pfizer in delivering a key treatment for COVID-19
As the world faced the worst pandemic in living memory, global pharmaceutical companies strove to rapidly discover and scale drug candidates which could address COVID-19. Codexis was able to support Pfizer in the synthesis of a critical intermediate for their COVID-antiviral, with a multi-ton production of enzyme to support tens of millions of treatments within a year from first clinical supply.